Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2005
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 167 citations in OpenAlex.
- Pooled it
- KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study.British journal of cancer · 2018Trial
- Melanoma's New Frontier: Exploring the Latest Advances in Blood-Based Biomarkers for Melanoma.Cancers · 2024Review
- Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Review
- Blood-based DNA methylation in advanced Nasopharyngeal Carcinoma exhibited distinct CpG methylation signature.Scientific reports · 2023Article
- Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction.Biomarker research · 2023Review
- Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets.Journal of personalized medicine · 2022Review
- Promising Blood-Based Biomarkers for Melanoma: Recent Progress of Liquid Biopsy and Its Future Perspectives.Current treatment options in oncology · 2022Review
- Identification of aberrantly methylated differentially expressed genes and pro-tumorigenic role of KIF2C in melanoma.Frontiers in genetics · 2022Article
- Methylation Markers in Cutaneous Melanoma: Unravelling the Potential Utility of Their Tracking by Liquid Biopsy.Cancers · 2021Review
- Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring.International journal of molecular sciences · 2021Review
- Unraveling the Wide Spectrum of Melanoma Biomarkers.Diagnostics (Basel, Switzerland) · 2021Review
- Review
- Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis.Journal of oncology · 2021Article
- Phenotypes from cell-free DNA.Open biology · 2020Article
- Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma.Cancers · 2019Article
- Prediction and Analysis of Skin Cancer Progression using Genomics Profiles of Patients.Scientific reports · 2019Article
- Diagnostic Value of Circulating Free DNA Integrity and Global Methylation Status in Gall Bladder Carcinoma.Pathology oncology research : POR · 2019Article
- Clinical and Prognostic Significance of OAnnals of dermatology · 2018Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
purposeCurrently, no validated blood-based assays accurately predict treatment response or outcome in melanoma patients. We hypothesized that methylation of tumor-related genes detected in serum DNA could predict disease outcome and therapeutic response in patients receiving concurrent biochemotherapy (BC) for metastatic melanoma. PATIENTS AND
methodsAmerican Joint Committee on Cancer stage IV melanoma patients (N = 50) had blood drawn before administration of BC. Patients (n = 47) were classified as BC responders or nonresponders. Responders (n = 23) demonstrated a complete or partial response following BC; nonresponders (n = 24) demonstrated progressive disease. Hypermethylation of Ras association domain family 1 (RASSF1A), retinoic acid receptor-beta2 (RAR-beta2), and O6-methylguanine DNA methyltransferase (MGMT) genes were assessed by methylation-specific polymerase chain reaction.
resultsCirculating methylated RASSF1A was significantly less frequent for responders (three of 23 patients; 13%) than nonresponders (10 of 24 patients; 42%; P = .028). Patients with RASSF1A, RAR-beta2, or at least one serum methylated gene had significantly worse overall survival than patients with no methylated genes (log-rank, P = .013, .021, and .01, respectively). Methylated RASSF1A was the only factor that significantly correlated with overall survival and BC response (risk ratio, 2.38; 95% CI, 1.16 to 4.86; P = .018; odds ratio = 0.21; 95% CI, 0.05 to 0.90; P = .036).
conclusionDetection of circulating methylated DNA in serum can predict response to BC and disease outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.